PLUR · Pluri Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $167.0K | $198.0K | $316.0K | $185.0K | $427.0K | $326.0K | $105.0K | $71.0K | $54.0K | $2.0K |
| Cost of Revenue | $111.0K | $112.0K | $201.0K | $74.0K | $291.0K | $126.0K | - | - | - | - |
| Gross Profit | $56.0K | $86.0K | $115.0K | $105.0K | $71.0K | $200.0K | - | - | - | - |
| R&D | $3.96M | $3.83M | $3.93M | $2.92M | $3.04M | $2.89M | $2.96M | $3.09M | $3.37M | $4.58M |
| SG&A | $2.63M | $2.77M | $2.53M | $2.14M | $2.49M | $2.51M | $2.35M | $2.51M | $2.44M | $2.90M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $128.0K | $129.0K | $65.0K | - | - | $65.0K | - | - | $67.0K | - |
| Operating Income | ($6.54M) | ($6.51M) | ($6.35M) | ($4.96M) | ($5.40M) | ($5.20M) | ($5.21M) | ($5.53M) | ($5.38M) | ($6.68M) |
| Interest Expense | $237.0K | $231.0K | $229.0K | $211.0K | $218.0K | $217.0K | $212.0K | $218.0K | $194.0K | - |
| Income Tax | ($8.0K) | ($8.0K) | ($8.0K) | - | - | - | - | - | - | - |
| Net Income | ($5.55M) | ($6.54M) | ($5.85M) | ($2.96M) | ($6.15M) | ($5.88M) | ($4.91M) | ($5.29M) | ($4.96M) | ($8.12M) |
| EPS - Basic | ($0.55) | ($0.71) | ($0.65) | ($0.53) | ($0.94) | ($1.08) | ($0.12) | ($1.01) | ($0.96) | ($1.92) |
| EPS - Diluted | ($0.55) | ($0.71) | ($0.65) | ($0.53) | ($0.94) | ($1.08) | ($0.12) | ($1.01) | ($0.96) | ($1.92) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.42M | $4.69M | $4.26M | $5.89M | $8.50M | $3.20M | $6.78M | $7.08M | $5.25M | $5.36M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $743.0K | $1.01M | $877.0K | $866.0K | $930.0K | $1.13M | $964.0K | $1.03M | $973.0K | $1.81M |
| Current Assets | $10.46M | $13.80M | $16.92M | $22.09M | $27.45M | $27.03M | $31.11M | $27.37M | $35.26M | $41.41M |
| Total Assets | $26.06M | $30.60M | $33.67M | $38.68M | $37.41M | $35.44M | $39.53M | $36.39M | $44.54M | $50.80M |
| Current Liabilities | $32.01M | $32.35M | $32.16M | $32.33M | $5.71M | $4.58M | $4.45M | $4.53M | $4.32M | $5.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($18.60M) | ($14.61M) | ($11.36M) | ($6.84M) | ($4.47M) | ($5.28M) | $96.0K | ($356.0K) | $8.90M | $13.36M |
| Retained Earnings | ($461.00M) | ($455.45M) | ($448.90M) | ($443.06M) | ($435.46M) | ($426.35M) | ($420.47M) | ($414.74M) | ($404.55M) | ($399.58M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.43M) | - | - | ($4.06M) | - | - | ($5.86M) | - |
| Investing Cash Flow | - | - | $3.85M | - | - | $585.0K | - | - | $5.80M | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | $116.0K | - | - | $208.0K | - | - | $103.0K | - |
| Free Cash Flow | - | - | ($5.54M) | - | - | ($4.27M) | - | - | ($5.96M) | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 33.5% | 43.4% | 36.4% | 56.8% | 16.6% | 61.3% | - | - | - | - |
| Operating margin | -3913.8% | -3285.9% | -2009.5% | -2679.5% | -1264.6% | -1594.5% | -4964.8% | -7794.4% | -9957.4% | -333950.0% |
| EBITDA margin | -3837.1% | -3220.7% | -1988.9% | - | - | -1574.5% | - | - | -9833.3% | - |
| Net margin | -3322.2% | -3304.5% | -1851.3% | -1597.8% | -1439.6% | -1804.3% | -4671.4% | -7454.9% | -9187.0% | -405850.0% |
| Free cash flow margin | - | - | -1754.4% | - | - | -1310.4% | - | - | -11037.0% | - |
| FCF / Net income | - | - | 0.95 | - | - | 0.73 | - | - | 1.20 | - |
| R&D / Revenue | 2372.5% | 1932.3% | 1244.0% | 1581.1% | 712.6% | 886.2% | 2822.9% | 4357.7% | 6233.3% | 228750.0% |
| SG&A / Revenue | 1574.9% | 1397.0% | 801.9% | 1158.4% | 583.8% | 769.6% | 2241.9% | 3536.6% | 4514.8% | 144800.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -21.3% | -21.4% | -17.4% | -7.6% | -16.4% | -16.6% | -12.4% | -14.5% | -11.1% | -16.0% |
| Return on equity | 29.8% | 44.8% | 51.5% | 43.2% | 137.4% | 111.3% | -5109.4% | 1486.8% | -55.7% | -60.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.33 | 0.43 | 0.53 | 0.68 | 4.81 | 5.90 | 6.98 | 6.05 | 8.16 | 7.37 |
| Quick ratio | 0.33 | 0.43 | 0.53 | 0.68 | 4.81 | 5.90 | 6.98 | 6.05 | 8.16 | 7.37 |
| Cash ratio | 0.11 | 0.14 | 0.13 | 0.18 | 1.49 | 0.70 | 1.52 | 1.56 | 1.22 | 0.95 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -27.6x | -28.2x | -27.7x | -23.5x | -24.8x | -24.0x | -24.6x | -25.4x | -27.7x | - |
| Equity multiplier | -1.40 | -2.09 | -2.96 | -5.65 | -8.36 | -6.71 | 411.74 | -102.22 | 5.00 | 3.80 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 2443d | 3305d | 1593d | 4271d | 1166d | 3271d | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | 2500.3x | - | 22.3x | 15.9x |
| P / S | 204.7x | 139.8x | 127.5x | 148.6x | 66.1x | 101.3x | 2286.0x | 476.5x | 3673.9x | 106222.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -60.9% | 7.0% | -3.1% | 76.2% | 501.4% | 503.7% | 5150.0% | -18.4% | -37.9% | - |
| Revenue CAGR (3y) | 24.3% | 362.6% | 53.7% | - | 22.2% | - | - | - | - | -55.7% |
| Revenue CAGR (5y) | - | - | - | 51.7% | - | - | - | - | - | -47.5% |
| Gross profit growth (YoY) | -21.1% | -18.1% | -42.5% | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -21.0% | -31.2% | -22.2% | 4.9% | 2.4% | 3.3% | 21.9% | 22.1% | 22.3% | 38.1% |
| Net income growth (YoY) | 9.7% | -121.3% | 0.5% | 39.7% | -16.1% | -18.6% | 39.6% | 30.6% | 19.0% | 25.8% |
| EPS growth (YoY) | 41.5% | -34.0% | 39.8% | -341.7% | 6.9% | -12.5% | 93.7% | -431.6% | -166.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -29.8% | - | - | 28.3% | - | - | 22.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -315.8% | -113.5% | -115.0% | - | -1156.7% | - | -99.3% | - | -63.2% | -55.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Pluri Inc. against the 5 most active filers in the same SIC group.